Work

Microneedle-based injection of Fungizone/Amphotericin B: an effective treatment for American cutaneous leishmaniasis in mice

Year: 2026
Type: article
Abstract: Amphotericin B (AmB) is a potent, accessible, FDA-approved drug against CL with damaging side effects. While newer lipid formulations have less toxicity, limitations include affordability and cold-chain requirements. CL affects mostly impoverished communities, which complicates travel to urban hospitals for treatment. Therefore, an off-clinic drug delivery system is desirable. Microneedles can deliver AmB directly to localized CL lesions, which we hypothesized would limit parasite growth without systemic toxicity. Thus, a three-by-three array of 1 mm tall stainless steel hollow microneedles was evaluated in this study. To test their efficacy, we utilized Leishmania mexicana-infected mice to model American CL. Following 20- and 10-consecutive day microneedle treatments (n = 5/group), the 20-day trials more strongly limited lesion growth by up to 2.8 mm versus a maximum 1.1 mm difference between the drug and placebo groups in the 10-day trial (p = 0.008, p = 0.075, respectively). Also, treatments were associated with reduced parasitic burden weeks after treatment cessation, as assessed by limiting dilution (p = 0.057 for 10-day, p = 0.075 for 20-day; one-tailed Mann‒Whitney U test). No elevation of blood serum creatinine or blood urea nitrogen levels was observed, supporting the hypothesis of lessened kidney toxicity. Additionally, flow cytometry explorations showed differences in IL-17 and IFN-γ positivity, and histological changes were observed in the upper dermis. These promising results represent the first test of hollow microneedles for CL treatment and pave the way for further trials. The adoption of microneedles could reduce CL burden in affected communities because of their ease of use, efficacy, and safety with a pre-approved drug.
Language: English
Open Access status: gold
Estimated APC paid: $2,864
Funders: Consejería de Universidad, Investigación e Innovación, Junta de Andalucía, National Science Foundation, National Aeronautics and Space Administration, Earthwatch Institute, Amgen, World Bank Group, Ohio State University, Japan Agency for Medical Research and Development, Nottingham Trent University, University of Manitoba, Environment Agency, Sir John Fisher Foundation, UK Research and Innovation, Amarin Corporation, Tromsø Forskningsstiftelse, Cycle for Survival, Dutch Cardiovascular Alliance, Geoffrey Beene Foundation, European Commission, National Research Foundation, Deutsche Forschungsgemeinschaft, Danmarks Grundforskningsfond, United States-Israel Binational Science Foundation, University of Queensland, Fundação de Amparo à Pesquisa do Estado de São Paulo, National Natural Science Foundation of China, Chinese Academy of Sciences, Austrian Science Fund, Seoul National University, Fundación Científica Asociación Española Contra el Cáncer, Generalitat de Catalunya, China Postdoctoral Science Foundation, Nederlandse Organisatie voor Wetenschappelijk Onderzoek, Generalitat Valenciana, Natural Science Foundation of Guangdong Province, Korea Health Industry Development Institute, National Research Foundation of Korea, Hjärt-Lungfonden, King Fahd University of Petroleum and Minerals, Shiraz University of Medical Sciences, Seoul National University Hospital, Vetenskapsrådet, Universiteit Gent, China Scholarship Council, Innovative Team of Jiangsu Province, Norges Forskningsråd, State Administration of Traditional Chinese Medicine of the People's Republic of China, Natural Science Foundation of Shandong Province, National Forestry and Grassland Administration, Qingdao University of Science and Technology, Shenzhen University, Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg, Novo Nordisk Fonden, Qinghai Provincial Department of Science and Technology, Business Finland, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Science and Technology Department of Tibet, LUPUS UK, Jazz Pharmaceuticals Canada, CRIS Cancer Foundation, National Institutes of Health, U.S. Food and Drug Administration, Directorate for Engineering, Horizon 2020 Framework Programme, Center for Innovations in Quality, Effectiveness and Safety, Canadian Institutes of Health Research, Central Council for Research in Homeopathy, Ministry of AYUSH, Government of India, Engineering and Physical Sciences Research Council, Natural Environment Research Council, Fundação para a Ciência e a Tecnologia, Centro de Investigación Científica y de Educación Superior de Ensenada, Baja California, Chinese Universities Scientific Fund, Yonsei University College of Medicine, European Regional Development Fund, Xinjiang Institute of Ecology and Geography, Chinese Academy of Sciences, Institute of Chemistry, Chinese Academy of Sciences, National Key Research and Development Program of China, Fundamental Research Funds for the Central Universities, Norwegian Institute of Public Health, Sino-Africa Joint Research Center, Chinese Academy of Sciences, Office of Naval Research, National Institute of Mental Health, National Institute on Drug Abuse, Fogarty International Center, National Institute of Biomedical Imaging and Bioengineering, Bioenergy Technologies Office, Los Alamos National Laboratory, NHLBI Division of Intramural Research, HORIZON EUROPE European Research Council, World Scleroderma Foundation, Advanced Materials and Manufacturing Technologies Office, NextGenerationEU, Key Research and Development Program of Zhejiang Province
OpenAlex ID: W7160232002
FWCI:
Cites: 112
Cited by:
Related to: 10